[PDF][PDF] Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
P Fenaux, GJ Mufti, E Hellström-Lindberg… - Journal of clinical …, 2010 - researchgate.net
Journal of clinical oncology, 2010•researchgate.net
Purpose In a phase III randomized trial, azacitidine significantly prolonged overall survival
(OS) compared with conventional care regimens (CCRs) in patients with intermediate-2–and
high-risk myelodysplastic syndromes. Approximately one third of these patients were
classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis
compared the effects of azacitidine versus CCR on OS in this subgroup.
(OS) compared with conventional care regimens (CCRs) in patients with intermediate-2–and
high-risk myelodysplastic syndromes. Approximately one third of these patients were
classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis
compared the effects of azacitidine versus CCR on OS in this subgroup.
Purpose
In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2–and high-risk myelodysplastic syndromes. Approximately one third of these patients were classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis compared the effects of azacitidine versus CCR on OS in this subgroup.
researchgate.net
